Table 2.
Logistic regression analysis exploring the relationship between anti-CCP/IgM RF and persistent arthritic disease
| Univariate | Multivariate* | |||||
|---|---|---|---|---|---|---|
| estimate | OR (95% CI) |
P | estimate | OR (95% CI) |
P | |
| Anti-CCP2 (units/ml) |
0.013 | 1.013 (1.008 to 1.018) |
<0.001 | 0.008 | 1.008 (1.003 to 1.013) |
0.002 |
| Anti-CCP2+ (>25 units/ml) |
2.102 | 8.184 (4.008 to 16.709) |
<0.001 | 1.272 | 3.567 (1.572 to 8.094) |
0.002 |
| IgM RF (units/ml) | 0.022 | 1.022 (1.012 to 1.033) |
<0.001 | 0.009 | 1.009 (1.001 to 1.017) |
0.026 |
| IgM RF+ (>25 units/ml) | 2.018 | 7.526 (3.677 to 15.407) |
<0.001 | 0.999 | 2.716 (1.189 to 6.202) |
0.018 |
| IgM RF+ and anti-CCP+ | 2.593 | 13.369 (4.658 to 38.369) |
<0.001 | 2.073 | 7.948 (2.659 to 23.752) |
<0.001 |
*Adjusted for age, sex, small joint arthritis (swelling of MTP-, PIP- and/or MCP joints), Health Assessment Questionnaire, 28-tender joint count, C-reactive protein (mg/l), morning stiffness >1 hour, as well as IgM rheumatoid factor (for the analysis with anti-CCP) or anti-CCP (for the analysis with IgM RF), respectively.